NEW YORK (TheStreet) -- Inovio Pharmaceuticals (INO) - Get Report stock is up by 7.13% to $8.72 in early afternoon trading on Wednesday, after the company reported that its Ebola vaccine caused "robust immune responses" in an initial trial of the treatment on humans.
The immunotherapy company announced on Wednesday that its Ebola vaccine generated "strong T cell and antibody responses" in a Phase 1 study. Ebola is a deadly virus that is characterized by fever, fatigu, and vomiting, according to the Centers for Disease Control and Prevention.
The trial, which received $45 million in funding from the U.S. Defense Advanced Research Projects Agency, has not caused any serious adverse affects, the company said in a statement.
"These initial data from our Ebola DNA vaccine represent just a first step in this DARPA-funded program," CEO J. Joseph Kim said in a statement. "We look forward to rapidly moving this DNA vaccine into larger human studies on the path to product licensure. We are also advancing our Ebola dMAb™ product and expect to clinically test that independently of the DNA vaccine approach."
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "sell" with a ratings score of D. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.
You can view the full analysis from the report here: INO